After helping Bristol-Myers Squibb develop the cancer drug Taxol and accumulating 10 patents related to its semi-synthesis in the process, Ivan Trifunovich took the natural next step: he went to Wharton for his MBA. “I saw a great need in bridging the R&D and science versus the commercial chasm,” he says. “To actually bring innovative medicines to market and to the patients, I think the dialogue between the two sides is critical and that’s something large pharma is always lacking.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.